OCDX - Ortho Clinical reverses losses after positive analyst reviews

Ortho Clinical Diagnostics ([[OCDX]] +3.1%) looks set to end the five-day losing streak after a string of positive sell-side remarks today.The analysts from Citi, Piper Sandler, BofA, Morgan Stanley, and JPMorgan have all initiated the coverage on the stock with buy-equivalent ratings. The price targets range from ~$20.00 to $27.00 per share.Citi has initiated the coverage with a buy rating and a price target of $20.00 implying ~19.1% upside to the previous close.Noting that Ortho Clinical is a pure-play diagnostic company, the analyst Patrick Donnelly expects the company to take share in the market for in vitro diagnostics as it ‘drives customer life-time value and executes on its enhanced commercial focus as an independent company.’Piper Sandler analyst Steven Mah with an overweight rating and a price target of ~$27.00 per share cites the aging population, increasing prevalence of chronic diseases, rising global access to healthcare, and the emergence of new diseases as

For further details see:

Ortho Clinical reverses losses after positive analyst reviews